Sign up to save your podcasts
Or
Share The Obesity Drug Loophole. Plus, the Outlook for Homebuilder Stocks.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Obesity Drug Loophole. Plus, the Outlook for Homebuilder Stocks.
Also, a top Vanguard strategist discusses the run-up in growth stocks.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Barron's
4.7
14741,474 ratings
Also, a top Vanguard strategist discusses the run-up in growth stocks.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Barron's Streetwise
View all
WSJ What’s News
4,362 Listeners
WSJ Your Money Briefing
1,753 Listeners
Investing Insights
497 Listeners
Motley Fool Money
3,195 Listeners
Exchanges
992 Listeners
Zacks Market Edge
298 Listeners
WSJ Minute Briefing
659 Listeners
Wall Street Breakfast
1,029 Listeners
Numbers by Barron's
376 Listeners
The Readback
213 Listeners
The Long View
885 Listeners
Thoughts on the Market
1,267 Listeners
Barron's Advisor
108 Listeners
Barron's Live
195 Listeners
Investing Experts
58 Listeners
The Markets
70 Listeners
WSJ's Take On the Week
132 Listeners
At Barron's
19 Listeners